SLC6A4 rs2555143: Understanding Serotonin Transporter Variants
The rs2555143 variant is a single nucleotide polymorphism located within the promoter region of the SLC6A4 gene, which encodes the serotonin transporter. Researchers study this variant to understand if it influences how individuals respond to certain antidepressant medications, though current evidence remains limited and mixed.
What each genotype means
High serotonin transporter expression
This genotype is associated with higher basal activity of the serotonin transporter compared to the short form. While some studies suggest this may correlate with improved response to certain antidepressants like citalopram, findings are inconsistent and contradictory across different medications and populations. Please discuss your medication response and treatment plan with your clinician or pharmacist, as many factors influence clinical outcomes.
Carried by approximately 32% of individuals in studied populations, though frequencies vary significantly by ancestry.
Intermediate serotonin transporter expression
This genotype represents a combination of the long and short promoter forms of the serotonin transporter gene. Research into how this specific combination affects antidepressant response has yielded mixed results, with some studies showing no clear association with efficacy for drugs like venlafaxine. Because evidence is limited and conflicting, you should consult your healthcare provider to discuss how this information relates to your specific treatment.
This is a common genotype, observed in approximately 49% of individuals in initial population studies.
Lower serotonin transporter expression
This genotype is associated with lower basal activity of the serotonin transporter compared to the long form. Clinical evidence regarding its impact on antidepressant response is inconsistent, with some research suggesting different outcomes for various medications while other studies find no association at all. Always discuss your medication choices and any concerns about treatment response with your doctor or pharmacist.
Carried by approximately 19% of individuals in initial population studies, with prevalence varying by ancestry.
What is rs2555143?
The rs2555143 variant is a specific change in the DNA sequence located in the promoter region of the SLC6A4 gene. A promoter region is a segment of DNA that acts as a control switch, determining how much of a protein is produced by a gene. Because rs2555143 sits in this regulatory area, scientists have long hypothesized that it might alter the expression levels of the serotonin transporter protein. This variant is often analyzed alongside other well-known polymorphisms in the same gene, such as the 5-HTTLPR insertion/deletion, to build a more complete picture of how genetic variation might influence brain chemistry. It is classified as a common variant, meaning it appears frequently across diverse human populations.
The Role of the SLC6A4 Gene
The SLC6A4 gene provides instructions for creating the serotonin transporter, a protein responsible for moving serotonin from the space between neurons back into the cells that released it. This process, known as reuptake, is a critical mechanism for regulating the amount of serotonin available in the brain. Serotonin is a neurotransmitter that plays a significant role in mood, sleep, and emotional regulation. Because many antidepressant medications, particularly selective serotonin reuptake inhibitors (SSRIs), work by blocking this transporter to increase serotonin levels, the SLC6A4 gene is a primary focus in pharmacogenomics. Variations in this gene are thought to potentially influence how effectively these medications can modulate serotonin levels in the brain.
Research and Evidence Strength
Research into rs2555143 and its impact on antidepressant response has yielded inconsistent results. While some studies have explored whether specific genotypes correlate with better or worse outcomes for patients taking SSRIs, the evidence is currently considered limited. Many clinical studies have failed to find a strong, consistent link between this specific SNP and treatment remission or side-effect profiles. Furthermore, the complexity of depression means that drug response is likely influenced by a combination of many genes, environmental factors, and individual health history, rather than a single genetic marker. Because of these mixed findings, this variant is not currently used in clinical practice to guide medication selection or dosing decisions.
Population Frequency
The rs2555143 variant is common across global populations. Its frequency can vary significantly depending on ancestral background, which is a common observation for many genetic markers in the SLC6A4 gene. Researchers emphasize that these frequency differences are important to consider when interpreting study results, as findings in one ethnic group may not necessarily replicate in another.
What This Information Means for You
It is important to understand that having a particular genotype for rs2555143 does not predict how you will respond to any specific medication. Genetic testing for this variant is not a standard diagnostic tool, and it cannot determine whether an antidepressant will be effective for you. If you are curious about how your genetics might relate to your treatment plan, the best course of action is to have an open conversation with your clinician or pharmacist. They can help you understand the role of pharmacogenomics in the context of your overall health, medical history, and current treatment goals. Never make changes to your prescribed medication regimen based on genetic information without consulting a qualified healthcare professional.
How common is this variant?
The rs2555143 variant is a common polymorphism found across diverse global populations, with allele frequencies varying by ancestry.
Frequently asked questions
Can rs2555143 predict if an antidepressant will work for me?
No. Current scientific evidence is limited and inconsistent, meaning this variant cannot be used to predict how you will respond to antidepressant medication.
Should I get a genetic test for SLC6A4 variants?
Genetic testing for this variant is not standard clinical practice. You should discuss the necessity and utility of any pharmacogenetic testing with your doctor.
Is rs2555143 the same as 5-HTTLPR?
No, they are different. While both are located in the SLC6A4 gene and are often studied together, rs2555143 is a single nucleotide polymorphism, whereas 5-HTTLPR is an insertion/deletion polymorphism.
Does this variant cause depression?
No. Depression is a complex condition influenced by many genetic, environmental, and lifestyle factors. A single variant like rs2555143 does not cause depression.
Sources & further reading
Educational information only, last refreshed 10/15/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2555143?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SLC6A4
Current evidence-based reviews conclude that SLC6A4 variants do not currently support actionable clinical antidepressant guidance.
3' UTR variant in the serotonin transporter gene influencing mRNA stability and emotional stress susceptibility in interaction with environmental trauma.
A functional A/G variant within the 5-HTTLPR locus of the serotonin transporter gene. While historically hypothesized to modulate stress reactivity, large-scale replication studies and meta-analyses have largely failed to confirm consistent associations with psychiatric phenotypes or treatment response.